Tardive Dyskinesia - Pipeline Review, H2 2015

Date: July 22, 2015
Pages: 56
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T2A62B9630BEN
Leaflet:

Download PDF Leaflet

Tardive Dyskinesia - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Tardive Dyskinesia - Pipeline Review, H2 2015’, provides an overview of the Tardive Dyskinesia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tardive Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tardive Dyskinesia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Tardive Dyskinesia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Tardive Dyskinesia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Tardive Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Tardive Dyskinesia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Tardive Dyskinesia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Tardive Dyskinesia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Tardive Dyskinesia Overview
Therapeutics Development
Pipeline Products for Tardive Dyskinesia - Overview
Pipeline Products for Tardive Dyskinesia - Comparative Analysis
Tardive Dyskinesia - Therapeutics under Development by Companies
Tardive Dyskinesia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Tardive Dyskinesia - Products under Development by Companies
Tardive Dyskinesia - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Contera Pharma ApS
Neurocrine Biosciences, Inc.
Synchroneuron Inc.
Teva Pharmaceutical Industries Limited
Tardive Dyskinesia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acamprosate calcium SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dipraglurant IR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Tardive Dyskinesia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dutetrabenazine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
valbenazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tardive Dyskinesia - Recent Pipeline Updates
Tardive Dyskinesia - Dormant Projects
Tardive Dyskinesia - Product Development Milestones
Featured News & Press Releases
Jun 16, 2015: Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top-Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia
Feb 03, 2015: Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of SD-809 in Tardive Dyskinesia
Oct 30, 2014: Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial for SD-809 in Tardive Dyskinesia
Oct 30, 2014: Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
Oct 20, 2014: Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
Jul 17, 2014: Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial for SD-809 in Tardive Dyskinesia
Feb 24, 2014: Synchroneuron Announces First Patient Dosed in Phase 2 Tardive Dyskinesia Clinical Trial
Jan 09, 2014: Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
Jan 06, 2014: Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Sep 09, 2013: Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Tardive Dyskinesia, H2 2015
Number of Products under Development for Tardive Dyskinesia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Tardive Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2015
Tardive Dyskinesia - Pipeline by Contera Pharma ApS, H2 2015
Tardive Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H2 2015
Tardive Dyskinesia - Pipeline by Synchroneuron Inc., H2 2015
Tardive Dyskinesia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Tardive Dyskinesia Therapeutics - Recent Pipeline Updates, H2 2015
Tardive Dyskinesia - Dormant Projects, H2 2015

LIST OF FIGURES

Number of Products under Development for Tardive Dyskinesia, H2 2015
Number of Products under Development for Tardive Dyskinesia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Addex Therapeutics Ltd
Contera Pharma ApS
Neurocrine Biosciences, Inc.
Synchroneuron Inc.
Teva Pharmaceutical Industries Limited
Skip to top


Tardive Dyskinesia - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 52 pages
Tardive Dyskinesia - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Dyskinesia - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 183 pages
Dyskinesia - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Tardive Dyskinesia - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: